48 results on '"DasGupta Bhaskar"'
Search Results
2. Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters
3. A 26‐week feasibility study comparing the efficacy and safety of modified‐release prednisone with immediate‐release prednisolone in newly diagnosed cases of giant cell arteritis
4. Eligibility for clinical trials in primary Sjögren’s syndrome: lessons from the UK Primary Sjögren’s Syndrome Registry
5. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
6. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
7. Eligibility for clinical trials in primary Sjögren’s syndrome: lessons from the UK Primary Sjögren’s Syndrome Registry
8. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
9. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica
10. 2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
11. Giant Cell Arteritis: Beyond Corticosteroids
12. Do the EULAR Sjögren’s syndrome outcome measures correlate with health status in primary Sjögren’s syndrome?
13. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK
14. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
15. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
16. Health-related utility values of patients with primary Sjögrenʼs syndrome and its predictors
17. VASCULITIS SYNDROMES: Dealing with increased vascular risk and mortality in GCA
18. Polymyalgia rheumatica in older adults
19. Imaging indications in polymyalgia rheumatica
20. Counterbalance of ligand- and self-coupled motions characterizes multispecificity of ubiquitin
21. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögrenʼs syndrome
22. Diagnosis and assessment of polymyalgia rheumatica: a step forward
23. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative
24. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
25. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors
26. Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly
27. Giant cell arteritis
28. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus
29. Current understanding and management of giant cell arteritis and polymyalgia rheumatica
30. BSR and BHPR guidelines for the management of giant cell arteritis
31. Concise guidance: diagnosis and management of giant cell arteritis
32. Concise guidance: diagnosis and management of polymyalgia rheumatica
33. BSR and BHPR guidelines for the management of polymyalgia rheumatica
34. Current advancements in the management of giant cell arteritis
35. Golimumab: a new anti-TNF agent on the horizon for inflammatory arthritis
36. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome
37. Musculoskeletal ultrasonography: to keep pace with progress or be left behind?
38. Autoimmunizing Mechanisms in Thymoma and Thymus
39. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
40. NET-SYNTHESIS: a software for synthesis, inference and simplification of signal transduction networks
41. Algorithmic Issues in Reverse Engineering of Protein and Gene Networks via the Modular Response Analysis Method
42. Reconstructing sibling relationships in wild populations
43. Clinical Outcomes, Quality of Life, and Diagnostic Uncertainty in the First Year of Polymyalgia Rheumatica
44. The Role of Mutant UDP-N-Acetyl-α-d-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis
45. Polymyalgia Rheumatica: The Mess We Are Now In and What We Need To Do About It
46. Inapproximability results for the lateral gene transfer problem*
47. Polynomial Time Approximation Scheme for Symmetric Rectilinear Steiner Arborescence Problem
48. Multi-phase Algorithms for Throughput Maximization for Real-Time Scheduling*
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.